Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US9346888B2 · kind B2 · utility
1Cited by
9References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2013 |
| Grant date | May 24, 2016 |
| Priority date | — |
| Expiry date | Jan 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/55
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.